

Effects of Macular Carotenoids on Eye, Brain, and Body




James M. Stringham, Ph.D.
Visual Performance Laboratory
Duke Eye Center
Duke University Medical School
Department of Ophthalmology
james.stringham@duke.edu



The Oxygen Paradox

Although indispensable for life, oxygen can be toxic.

- Reactive oxygen species (e.g. singlet oxygen, superoxide radicals)
- Oxidative stress



Oxidation, sped along by an electrolyte (salt)

1

2

The "Rusty Pipe Wrench Experiment"



The "Rusty Pipe Wrench Experiment"



3

4

The "Rusty Pipe Wrench Experiment"



5

6

Lutein, Zeaxanthin, & Mesozeaxanthin

- Carotenoids**
 - Pigments that give fruits and vegetables their color
- Exceptional antioxidants
 - Xanthophyll carotenoids capable of triplet excitation transfer
 - Can quench free-radical oxygen, regenerate
- Lutein, zeaxanthin, and mesozeaxanthin appear yellow—orange...absorb harmful blue light (see figure on right)
- Combine to form "macular pigment" in the retina

Macula lutea ("yellow spot")

- MPOD ranges from 0 to 1.65 OD
 - Can reach extremely high concentration
- The average American does not consume enough leafy greens (e.g. kale, spinach, broccoli) to raise MPOD to meaningful levels (NHANES, 2013-2014).
 - Average American = 0.30 MPOD
 - Significantly improved ocular health / visual performance seen at values of 0.70 and beyond



- The Hadza tribe (northern Tanzania)**
- One of the few remaining hunter-gatherer societies on earth.
 - Microbiome is exceptionally diverse (Schnorr et al. 2014)
 - **The majority of the annual Hadza diet (~70% of kilocalories) comes from plant foods.**
 - Birds, small, medium and large-sized game meat comprise ~30% of the annual diet
 - The human gastrointestinal tract is increasingly recognized as the gateway to pathogenic, metabolic and immunologic diseases
 - Hadza have relatively low rates of infectious disease, metabolic disease and nutritional deficiencies compared to all other human populations

7


Emerging from the “Stone Age” of Macular Carotenoid Research

Antioxidants!

Blue-light filtration!

Protect against AMD!

...only after diagnosis of intermediate AMD...?



Convergent new research from several disciplines indicates complex, significant benefits of high L, Z, and MZ. **Across the lifespan.**

8

Where we started: Higher dietary intake of carotenoids, higher MPOD reduces risk for developing AMD

Original Contributions

Dietary Carotenoids, Vitamins A, C, and E, and Advanced Age-Related Macular Degeneration

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.


Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.


Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

Johnson CL, Smith L, Johnson CL, et al. 1995. *Journal of the American Medical Association* 274:1548-1554.

9



10




11

Reduction of drusen in AMD


Case: 87 YOWM, L, Z, MZ x 12 months – OD
(courtesy Gary Morgan)

Intermediate AMD

Reduced drusen



9/22/17




10/18/18

12

Visual performance in early-stage AMD patients:


- 2-year L, Z, MZ supplementation trial
 - 75% of 88 patients' visual performance improved
 - 29 of 25 parameters of visual performance shown to improve over two years
 - Contrast sensitivity (see bottom figure on right), reading speed, glare disability all improved significantly
 - Only 2 patients in entire sample progressed along AREDS severity scale (only 1 step more severe).
 - Response to supplementation was very strong, promising

Hardy AL, Seelye JL, Patel L, Stark L, Brinkman SM, Hardy D, Jiang L, Conner L, Miller BA. The impact of supplemental antioxidants on visual function in non-dominant age-related macular degeneration: a randomized clinical trial. 2018. *Investigative Ophthalmology and Visual Science*.




13

Brain Growth and Synaptogenesis Continue Throughout Pregnancy, and Neonatally...RAPIDLY!



14


Oxidative stress in the infant retina



Hardy et al. 2000, *Cardiovascular*, 47, 499-509.

15


Lutein and Zeaxanthin in the Womb: Transfer From Vitreous Humor to Retina and Lens



With permission from Springer Science & Business Media Publishers, et al. *Cell Open Biol* 2019; 1(4):0000000.

16

After baby is born...why is colostrum yellow...?




Melton C, Schaefer ET, Ann Rev Med Sci. 1981;45:85-95.

17

EARLY Functional Vision Benefits


Premature infants consuming lutein-supplemented formula exhibit signs of enhanced neural development in the retina



From Ruzin et al. *J Perinatol* 2011; 31:1.


18

Lutein in the brain of term vs. preterm infants




19

Infants and children accumulate the macular carotenoids in their retinas (macular pigment):




20

Tissue uptake of carotenoids in growing chickens is related to carotenoid exposure during embryonic development



21

Early diet matters: lutein and zeaxanthin-fed monkey vs. diet devoid of carotenoids



22

Why Do We Accumulate Macular Carotenoids?

Visual Performance

What is Visual Performance?


Acuity...?
Vision is a complex process

1. Speed: Temporal resolution
 - a. Reaction time
 - b. Prediction
 - c. Decision time

2. Contrast sensitivity

3. Glare


4. Visual adaptation (photopigment kinetics)



23

24

Macular pigment and Visual Performance




How? At least four ways:

1. Healthy tissue
 - Lower oxidative stress, inflammation allows tissues to function more efficiently
2. Epigenetics
 - Endogenous antioxidant / physiological enhancement systems "switched on" in presence of L, Z, MZ
3. Light filtration
 - Glare effects (visual discomfort, disability glare, photostress recovery)
4. Physiology (neurophysiology)
 - Contrast sensitivity, visual processing speed, enhanced visual cycle kinetics


25

Brain activation (fMRI) while processing a simple foveal stimulus:



26

Retinal response to supplementation with L, Z, and MZ:




Consistent consumption of at least 12 mg / day of L / Z / MZ significantly increases MPOD (usually within 6 months)


27

The Nrf2 pathway: Lutein and Zeaxanthin Enhance Expression of Genes that Significantly Benefit the Retina^{1,2}

- Nrf2: Regulates the transcription of genes that process and eliminate carcinogens and toxins as well as the transcription of many genes with direct or indirect antioxidant effects (e.g., glutathione, superoxide dismutase, and catalase).
- Prevent cell death
- Enhance neurophysiological performance (ATP)
- Upregulated transcription levels ranged from 3.3 to 4.5 fold.



Effect of lutein on Nrf2 activation (from Frede et al.)



Z / MZ enhances glutathione trans/pren activity (top) and restores cellular ATP levels (bottom)

28



Visual Acuity is One Aspect of Visual Performance

1852: Dutch ophthalmologist Herman Snellen developed the Snellen chart to study visual acuity.

Visual acuity is a resolution task, determined primarily by the optics of the eye.

- It has become the basis for the judgment of visual performance.



Visual acuity testing is like auditory testing with a single intensity level across frequencies



29

Visual Performance in the Real World

Contrast sensitivity, acuity, and the perception of "real-world" targets


Overly & Sloan (1987): Contrast sensitivity at middle and low spatial frequencies (e.g. 6 cpd) was significant predictor of real-world object detection and identification. Faces, road signs, basic objects.

- CS determined to be a better predictor of performance than age!
- VA was not a significant contributor to real-world visual performance.




30

The Contrast Sensitivity Function



Contrast Sensitivity vs. Visual Acuity

One may read 20/20, but may exhibit a wide range of CS:




Courtesy Mark Bouak, OD

31

32


High MPOD leads to enhanced neurophysiology, improved contrast sensitivity:



Stringham et al. 2017; Nolan et al. 2016; WolfSchnurbauch et al. 2015; Stringham et al. 2011

33

Visual Performance: MPOD is related to faster visual processing




Derived from Hammond J. R., Weckstein B. R., *Optical Physics Optics*, 2015, 25-345-349.
see also Stringham & Stringham (2017), Patel et al. 2015, Stringham et al. 2017


Coincidence anticipation timing device
Reaction time, prediction better with higher MPOD
From Bowler et al. 2014

34

Blue light filtration = reduced oxidative stress:



35



36


High vs. Low MPOD: Glare Disability Reduced



Stringham & Hammond, Optom Vision Sci. 2008;85(2):65; Hammond et al. Invest Ophthalmol Vis Sci. 2014;55(12):8589-9; Holen et al. [2016]; Stringham et al. [2016]

37


Effects in Glare: Higher MPOD = Lower Visual Discomfort



Stringham et al. [2012]

38

Photostress recovery and the "fatigue function"



- MPOD is related to photostress recovery time
- Increases in MPOD via supplementation with L, Z, and MZ significantly reduce PSRT*

See also Stringham & Hammond, 2008; Potay et al. 2013; Hammond et al. 2014; Stringham et al. 2016

39





Fig. 5 PSRT "fatigue function" at baseline for four subjects with different MPOD. Functions fit with 8-spline interpolation. See text for explanation.


Repeated exposures of a bright flash of light reveal fatigue in photostress recovery for those with low MPOD

MPOD Associated With Better Vision in Dim Light, Faster Dark Adaptation



Stringham et al. 2013

40



*Stringham & Hammond, 2008; Hammond et al. 2006; Potay et al. 2013; Hammond et al. 2014; Stringham et al. 2016

Full circle: Macular Carotenoids and AMD


Case: 67 YOWM, L, Z, MZ x 12 months – OD
(courtesy Gary Morgan)

Intermediate AMD

Reduced drusen



9/22/17




10/18/18

41

OCT:

Although improved over the previous year, there are clear signs of drusen, and intermediate AMD.

Typically, this kind of situation results in severely impaired dark adaptation



42


Case: 10/18/2018, L, Z, MZ x 12 months →
Dark Adaptation

Dark Adaptation Test Results

DOB: 01-27-1951; Patient ID: 40127

Test Eye: Right
Test Date: 10-19-2018 10:33
Age at Test: 67
Protocol: Rapid Test
Pupil Size: 4.00 mm
Prescription: --
Trial Lens: --

6 minutes is considered the point of DA impairment



Rod Intercept is 4.36 minutes.
Fixation Error Rate is 0%.


Comments: AMD Maculopathy for 1 yr

Systemic & Cognitive Findings: Young, Healthy Individuals

43

44

Carotenoids are in the eye and throughout the central nervous system




45

Relationship Between Carotenoids in the Eye and the Brain


Macular pigment carotenoids in the retina and occipital cortex are related in humans

2016



46

Carotenoid concentration in the brain (mean of 4 brain regions; age 0-1 yrs)




Vishwanathan R, et al. *Acta Biologica Cracoviensia* 2011; 53 (suppl 1): Abstract 1.23

47

Pre-adolescent children (7-13 yrs.): Relationship between MPD and Intellectual Ability / Executive Processes

- On average, children with higher MPD:
 - Exhibit higher intellectual ability ($r = 0.268$; $p < 0.05$)
 - Verbal comprehension, concept formation, and visual matching
 - Score higher on tests of executive functioning ($r = 0.288$; $p < 0.05$)
 - Higher-order cognitive abilities, including goal-directed behavior, planning, judgment, reasoning, and problem solving.



48




New data:

1. Does macular carotenoid supplementation improve cognitive performance in young, healthy adults (18-35 yrs) in 6 months' time?
 - a. If so, are the effects related to changes in inflammatory / oxidative stress / neuroplasticity parameters, or MPOD?




49


Results: Cytokines, BDNF, and antioxidant capacity



50



Cognitive Effects:



51

Supplementation with macular carotenoids reduces psychological stress, serum cortisol, and sub-optimal symptoms of physical and emotional health in young adults

Nicole Tressa Stringham^{1,2,3}, Philip V. Holman^{1,2}, James M. Stringham^{1,2,3}

¹Neuroscience Research Program, Biomedical and Health Sciences Institute, University of Toronto, Toronto, ON, Canada; ²Department of Psychology, University of Toronto, Toronto, ON, Canada; ³Department of Neuroscience, University of Toronto, Toronto, ON, Canada


Benton (2012): Given the complexity and metabolic demands of the brain, signs of subclinical nutrient deficiency will manifest first as "disruption of normal brain functioning"

- 1-year study, supplementation with L, Z, and MZ
- Goal: Determine whether supplementation influences blood cortisol, psychological stress, and symptoms of emotional health.




52

A study on psychological stress. Hmm...where to find research participants?



53

Effects: 12 months later



Versus placebo:

- MPOD increased significantly
- Cortisol decreased significantly (dramatically)
- Psychological stress decreased significantly

Versus placebo, symptoms of suboptimal psychological and physical health decreased significantly:

- BAI
- BAI
- BAI
- SHSQ-25

54

Cognitive Findings in the Elderly, Including Early Alzheimer's Disease

55

First evidence: Lutein and DHA improved memory, learning, and executive function in older women

- 12 mg lutein and/or 800mg DHA improved:
 - Memory scores
 - Verbal fluency
 - Rate of learning



Source: University of Maryland, Baltimore, 2010

56

Carotenoids in the Brain Preserve Cognitive Performance

MPOD significantly associated with:

1. Better global cognition
2. Better verbal learning and fluency
3. Better memory recall
4. Faster processing speed
5. Faster perceptual speed

Cognitive function measures	Serum L + Z	MPOD
SMS	-0.111	0.269*
SRT: learn	0.087	0.263*
SRT: delayed recall	0.082	0.228*
Reaction time	0.082	-0.109
Verbal fluency	-0.12*	0.249*
Digit-symbol substitution task	-0.016	0.249*
Box fitting task	-0.087	0.154
Pattens comparison task	-0.127	0.190*

SMS, Teng Modified Mini-Mental State Examination; SRT, Rushdie Selective Reminders Task.

*P < 0.05.




n = 108,
77.6 +/- 2.7 years

*Important point: Correlations were not determined between serum L/Z and cognition. Only retina / brain levels. Long-term accumulation in neural tissues is key.

57

Carotenoid concentrations in the brain, for those 80 – 107 years old, as a function of cognitive status:




58

Macular Carotenoid Status in Early-Stage Alzheimer's Disease Patients:

(from Nolan et al. 2015)

Early – stage Alzheimer's disease patients have significantly lower MPOD, compared to matched normal controls



59

Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined

John M. Nolan*, Bruce M. Nolan*, Andrew P. Bush*, David M. Bush*, and John M. Nolan*

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA


Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA


Department of Psychology, University of Maryland, Baltimore, Baltimore, Maryland, USA

New trial shows promise for limiting progression of AD


- 18-month study
- Patients with mild, moderate, and severe AD were supplemented daily with 22 mg total L, Z, MZ combined with 1 g fish oil (430 mg DHA)
- Progression of AD was significantly less for this group (p = 0.003)
 - Caregivers reported functional benefits in memory, sight, and mood
- *New study planned at Duke to confirm these results



60




61




62

“Getting out in front of” age-related visual problems:



63



64

Conclusions

The macular carotenoids have several, significant benefits across the lifespan:

- Ocular / visual development
- Visual health and performance
- Phase II (epigenetic) effects
- Cognitive health and performance
 - Across the lifespan
 - May prolong onset of age-related cognitive decline
 - May preserve function in midst of disease

...oh, and relatively high MPOD can help reduce the risk of / slow the progression of AMD!

All of these effects can facilitate a conversation about nutrition with patients

65

Acknowledgments

Collaborators

UGA: Phil Holmes

US Army Aeromedical Research Laboratory: Kevin O'Brien

Air Force Research Laboratory: Leon McLin, Peter Smith, Paul Garcia

Duke: Felipe Medeiros, Alessandro Jammal, Tais Estrela, Eduardo Mariotttoni, Carlo Urata

University of the Incarnate Word Optometry School: Brian Foutch

Allisonville Eye Care Center (IN): Mark Roark

66